Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shieldin complex subunit 2 pseudogene 1 (SHLD2P1) is classified as a pseudogene in the human genome[1]. It is annotated as a non-functional copy of the parental gene SHLD2, which encodes a functional protein involved in DNA double-strand break repair as part of the shieldin complex. Unlike SHLD2, SHLD2P1 does not produce a functional protein product and is not known to play a direct molecular role in any biological process or disease pathology[1]. **Pseudogene status:** SHLD2P1 is a pseudogene, not a protein-coding gene, meaning it is typically considered a genomic remnant derived from a functional gene but is no longer translated into a functional protein[1]. It should not be confused with SHLD2, which encodes a key component of the DNA repair shieldin complex[3][4][5][7][8]. **Therapeutic relevance:** As a pseudogene, SHLD2P1 is not considered a therapeutic target such as a receptor, enzyme, transporter, or signaling molecule[1]. **Aliases:** Many alternative names reference its relation to the FAM35 gene family and pseudogene status but do not indicate it has a biochemical function[1]. **Disease and function:** There is no known functional or disease association for SHLD2P1, nor are there any known drugs targeting it, mechanisms of action, or biomarker utility[1]. **Incorrect status:** The query confuses the pseudogene SHLD2P1 with the functional gene SHLD2, which may be relevant for DNA repair, genome stability, and cancer biology, but SHLD2P1 itself is not a bona fide drug target[1][3][7][8]. If you are interested in the functional shieldin complex component, see “Shieldin complex subunit 2 (SHLD2)” for structured target information.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shieldin complex subunit 2 pseudogene 1 (SHLD2P1).